| Baseline | Week 12 | |||||
---|---|---|---|---|---|---|---|
All patients | Group 1 | Group 2 | All patients | Treatment group 1 | Treatment group 2 | ||
N | Â | 30 | 13 | 17 | 23 | 10 | 13 |
CTx ng/L | Median (IQR) | 191 (104, 387) | 142 (117, 287) | 218 (88, 387) | 223 (106, 381) | 155 (106, 225) | 308 (179, 423) |
BSAP IU/L | Median (IQR) | 18 (14, 30) | 16 (14, 30) | 18 (14, 29) | 17 (14, 29) | 16 (12, 29) | 18 (16, 25) |
TGF-β, ng/ml | Median (IQR) | 22.5 (17.1, 26.3) | 24.8 (20.7, 26.3) | 20.3 (17.1, 25.5) | 21.5 (15.8, 26.6) | 21.7 (15.0, 26.6) | 21.5 (18.0, 25.7) |
Activin- A, pg/ml | Median (IQR) | 597 (419, 1528) | 795 (517, 1164) | 519 (404, 1666) | 560 (483, 1045) | 616 (483, 1153) | 560 (526, 755) |
NTx 2nM BCE/mM creatine | Median (IQR) | 158 (73, 282) | 159 (60, 298) | 149 (87, 268) | 258 (121, 338) | 299 (94, 338) | 230 (137, 342) |
P1NP ng/ml | Median (IQR) | 56 (48, 91) | 70 (48, 96) | 55 (4, 80) | 54 (38, 75) | 55 (36, 75) | 54 (52, 60) |
BSP ng/ml | Median (IQR) | 34 (13, 60) | 39 (10, 73) | 32 (16, 55) | 17 (5, 21) | 18 (16, 21) | 14 (5, 36) |
FACT-BP | Median (IQR) | 13 (5, 25) | 8 (5, 14) | 16 (11, 26) | 13.5 (8, 18) | 11 (8, 17) | 14 (11, 18) |
BPI | Median (IQR) | 16 (0, 32) | 4 (0, 29) | 19 (6, 57) | 14.5 (2, 21) | 13 (1, 20) | 15 (7, 21) |
# of SRE (%), on or post study (n = 25) | 0 | 11 (44.0) | 5 (45.5) | 6 (42.9) | 18 (72.0) | 8 (72.7) | 10 (71.4) |
1 | 9 (36.0) | 3 (27.7) | 6 (42.9) | 3 (12.0) | 2 (18.2) | 1 (7.1) | |
2 | 5 (20.0) | 3 (27.7) | 2 (14.3) | 3 (12.0) | 1 (9.1) | 2 (14.3) | |
3 | Â | Â | Â | 1 (4.0) | 0 (0.0) | 1 (7.1) |